Xilio Therapeutics Inc (XLO) Stock Price, Quote & News

Company Profile

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX...

Industry: Biotechnology

Sector: Healthcare

Phone: 857-524-2466

Website: xiliotx.com

Address:

828 Winter Street, Suite 300, Waltham, United States

ScalpTrader_Portugal Jul. 29 at 9:11 PM

$QH never 4 get. paraboljoker, wolfofwallstreet, DaBullRunner and dbr_island (its the same guy) are the biggest scammers of Stocktwits. When they alert you to buy something, run, they need to sell their shares. This last guy alerted $XLO when it was at 1,10. Look where it is now.

1 · Reply

ScalpTrader_Portugal Jul. 28 at 5:46 PM

$QH THIS GUY IS A SCAMMER. why dont u talk about $XLO when u alerted at 1,10 and since then, down to 0,68? Guys like u dont care about others, guys like u alert for any stock when u need to exit. U are DabullRunner, 2 accounts, the same scammer. U only talk here in SW when u make money, do the same when u lose and make others lose SCAMMER

0 · Reply

Pharma_Stock_Calls Jul. 28 at 1:26 PM

$XLO watch it

0 · Reply

lookigotmeadollar Jul. 25 at 2:51 AM

$XLO what makes you think that? they just did an offering that raised 51M hence current stock price and not $1.10 it was post conference. their cash runway extends WELL into 2026, which is all they need for vilastobart

1 · Reply

MoneyPennyStocks Jul. 24 at 7:19 PM

$XLO The CEO is going to dilute this again Ill wager.

1 · Reply

Biotech_Beast Jul. 23 at 2:34 PM

$XLO This junk requires patience. Some clarity with Q2'25 on upcoming catalysts and their timelines would be nice.

1 · Reply

Devante14 Jul. 22 at 9:07 PM

$XLO when will this thing do something

1 · Reply

Dani_G_German Jul. 22 at 5:24 PM

$XLO 666 🧐

1 · Reply

8_seconds Jul. 22 at 3:48 PM

$XLO this thing can’t find a floor 🤬

1 · Reply

CagedMoney Jul. 22 at 1:09 AM

$XLO 👀

0 · Reply

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 10, 2025, 4:30 PM EDT - 7 weeks ago

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

Jun 5, 2025, 6:38 PM EDT - 7 weeks ago

Xilio Therapeutics Announces Closing of $50.0 Million Public Offering

Jun 2, 2025, 8:46 AM EDT - 2 months ago

Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering

Jun 2, 2025, 6:11 AM EDT - 2 months ago

Xilio Therapeutics Announces Proposed Public Offering

May 31, 2025, 8:00 AM EDT - 2 months ago

Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

May 8, 2025, 7:30 AM EDT - 2 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

May 2, 2025, 4:30 PM EDT - 3 months ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2025, 4:30 PM EDT - 3 months ago

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Apr 4, 2025, 4:30 PM EDT - 4 months ago

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 11, 2025, 7:30 AM EDT - 5 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:30 PM EST - 5 months ago

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 10:44 AM EST - 5 months ago

Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?

Feb 12, 2025, 7:35 AM EST - 5 months ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Feb 12, 2025, 7:33 AM EST - 5 months ago

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Jan 21, 2025, 5:05 PM EST - 6 months ago

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer

Jan 17, 2025, 4:30 PM EST - 6 months ago

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2024, 7:30 AM EST - 7 months ago

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Dec 16, 2024, 7:30 AM EST - 8 months ago

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

Nov 7, 2024, 9:15 AM EST - 9 months ago

Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors

Nov 7, 2024, 9:05 AM EST - 9 months ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results

Oct 30, 2024, 9:01 AM EDT - 9 months ago

Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Oct 4, 2024, 9:05 AM EDT - 10 months ago

Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Aug 28, 2024, 4:01 PM EDT - 11 months ago

Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results

Jun 13, 2024, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D.

May 14, 2024, 7:30 AM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

Apr 1, 2024, 4:05 PM EDT - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

Mar 28, 2024, 7:05 AM EDT - 1 year ago

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILD

Feb 28, 2024, 4:01 PM EST - 1 year ago

Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference

Jan 31, 2024, 4:01 PM EST - 1 year ago

Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference

Jan 8, 2024, 7:30 AM EST - 1 year ago

Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies

Dec 7, 2023, 7:30 AM EST - 1 year ago

Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data

Nov 9, 2023, 4:01 PM EST - 1 year ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results

Nov 3, 2023, 12:00 PM EDT - 1 year ago

Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors

Oct 31, 2023, 9:15 AM EDT - 1 year ago

Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting

Sep 27, 2023, 5:02 PM EDT - 1 year ago

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 5, 2023, 8:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D.

Sep 5, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Aug 14, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

May 25, 2023, 5:01 PM EDT - 2 years ago

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

Mar 2, 2023, 4:05 PM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Present at Upcoming Investor Conferences

Feb 16, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

Feb 2, 2023, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day

Nov 23, 2022, 7:30 AM EST - 2 years ago

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

Nov 9, 2022, 7:30 AM EST - 2 years ago

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

ScalpTrader_Portugal Jul. 29 at 9:11 PM

1 · Reply

ScalpTrader_Portugal Jul. 28 at 5:46 PM

0 · Reply

Pharma_Stock_Calls Jul. 28 at 1:26 PM

$XLO watch it

0 · Reply

lookigotmeadollar Jul. 25 at 2:51 AM

1 · Reply

MoneyPennyStocks Jul. 24 at 7:19 PM

$XLO The CEO is going to dilute this again Ill wager.

1 · Reply

Biotech_Beast Jul. 23 at 2:34 PM

$XLO This junk requires patience. Some clarity with Q2'25 on upcoming catalysts and their timelines would be nice.

1 · Reply

Devante14 Jul. 22 at 9:07 PM

$XLO when will this thing do something

1 · Reply

Dani_G_German Jul. 22 at 5:24 PM

$XLO 666 🧐

1 · Reply

8_seconds Jul. 22 at 3:48 PM

$XLO this thing can’t find a floor 🤬

1 · Reply

CagedMoney Jul. 22 at 1:09 AM

$XLO 👀

0 · Reply

M1LL5 Jul. 18 at 1:40 PM

$XLO steady as she goes 👍🏻

0 · Reply

deerix Jul. 18 at 1:05 PM

$XLO don't forget this one, just saying

0 · Reply

Suffix Jul. 17 at 10:00 PM

$XLO starter today, avg $.73 little high for my taste but this should run well when she does

1 · Reply

CagedMoney Jul. 17 at 7:39 PM

$XLO been too quiet… I sense an update this month.

0 · Reply

LesterDiamond99 Jul. 17 at 3:21 PM

$XLO

0 · Reply

LetsCHere Jul. 17 at 3:04 PM

$XLO

0 · Reply

deerix Jul. 17 at 2:58 PM

$XLO

0 · Reply

Skeetz99 Jul. 17 at 1:07 PM

$XLO How many O/S shares? Around $52MM per the Dilution tracker site? See below. There are lots of warrants; but they aren’t exercised yet.

0 · Reply

MrSixShots Jul. 15 at 10:31 PM

$XLO

2 · Reply

8_seconds Jul. 15 at 3:38 PM

$XLO only 45K volume on a .72 cent/share stock. Wow, this thing is stagnant

0 · Reply

lookigotmeadollar Jul. 11 at 6:00 PM

$XLO it’s more than seeing potential… 50k shares would be seeing potential, 7,00,000 shares? it’s more than potential. they have to have inside knowledge no way GKCC makes this big of a move without some sort of security. that’s over 5M worth of capital invested

2 · Reply

biohuntress Jul. 11 at 5:35 PM

$XLO GKCC did a private placement for 11% of INKT which went crazy today.....they did a 15% private placement with XLO......they must see some potential here I would think

0 · Reply

Market Cap	36.08M
Revenue (ttm)	6.34M
Net Income (ttm)	-58.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-918.61%
Debt to Equity Ratio	0.00

Volume	310,705
Avg Vol	611,222
Day's Range	N/A - N/A
Shares Out	51.78M
Stochastic %K	22%
Beta	-0.15
Analysts	Strong Sell
Price Target	$4.00